Iovance Biotherapeutics announced promising results from a real-world study of its commercially available Amtagvi® (lifileucel) for treating advanced melanoma in patients previously treated with ...
Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...
On August 28,2025, NASS announced the cancellation of the Farm Labor Survey. The discontinuance was officially posted to the Federal Register on September 3. Countless stakeholders including farmers, ...
Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...
Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...
In a paper initially prepared for the planning meeting for this review, Peytchev (2013) observes that drawing “unbiased inference from probability-based surveys relies on the collection of data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results